- Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients — Recruiting • Infectious Disease • NCT05234723.
- Study examined risk factors for ganciclovir-resistant CMV infection in organ and stem cell transplant patients to improve future prevention and treatment.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). Aims of the study are to investigate the incidence of and risk factors for GCV-RR CMV infection in SOT recipients and HSCT patients in order to design further studies aimed at preventing and improving the patient management of GCV-RR CMV infections. Conditions: Cytomegalovirus Infections Lead Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Planned Enrollment: 100 participants